TY - JOUR
T1 - Effect of systemic beta-blockers, ace inhibitors, and angiotensin receptor blockers on development of choroidal neovascularization in patients with age-related macular degeneration
AU - Thomas, Akshay S.
AU - Redd, Travis
AU - Hwang, Thomas
N1 - Publisher Copyright:
Copyright © by Ophthalmic Communications Society, Inc. Unauthorized reproduction of this article is prohibited.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Purpose: Recent studies have suggested that the use of systemic beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers can induce regression of choroidal neovascularization in rodent models. The purpose of this study is to evaluate if these agents have a protective effect against the development of choroidal neovascularization in patients with age-related macular degeneration. Methods: In this single-center retrospective case-control study, the charts of 250 patients with neovascular age-related macular degeneration were compared with those of 250 controls with dry age-related macular degeneration. Charts were reviewed for current and past use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers. Frequency tables were generated, and associations were examined using chi-square tests, t-tests, and multivariate logistic regression. Results: There was no statistically significant difference between rates of beta-blocker use (P = 0.57), angiotensin-converting enzyme inhibitors use (P = 0.20), or angiotensin receptor blockers use (P = 0.61) between the 2 groups. Additionally, there was no statistically significant difference between rates of use of combinations of the above drugs between the two groups. Conclusion: Although there is growing evidence that beta-blockers, angiotensinconverting enzyme inhibitors, and angiotensin receptor blockers can induce regression of choroidal neovascularization in rodent models, these medications do not seem to confer a protective effect against the development of choroidal neovascularization in patients with age-related macular degeneration.
AB - Purpose: Recent studies have suggested that the use of systemic beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers can induce regression of choroidal neovascularization in rodent models. The purpose of this study is to evaluate if these agents have a protective effect against the development of choroidal neovascularization in patients with age-related macular degeneration. Methods: In this single-center retrospective case-control study, the charts of 250 patients with neovascular age-related macular degeneration were compared with those of 250 controls with dry age-related macular degeneration. Charts were reviewed for current and past use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers. Frequency tables were generated, and associations were examined using chi-square tests, t-tests, and multivariate logistic regression. Results: There was no statistically significant difference between rates of beta-blocker use (P = 0.57), angiotensin-converting enzyme inhibitors use (P = 0.20), or angiotensin receptor blockers use (P = 0.61) between the 2 groups. Additionally, there was no statistically significant difference between rates of use of combinations of the above drugs between the two groups. Conclusion: Although there is growing evidence that beta-blockers, angiotensinconverting enzyme inhibitors, and angiotensin receptor blockers can induce regression of choroidal neovascularization in rodent models, these medications do not seem to confer a protective effect against the development of choroidal neovascularization in patients with age-related macular degeneration.
KW - ACE inhibitor
KW - Age-related macular degeneration
KW - Angiotensin receptor blocker
KW - Betablocker
KW - Choroidal neovascularization.
UR - http://www.scopus.com/inward/record.url?scp=84942433500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942433500&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000000603
DO - 10.1097/IAE.0000000000000603
M3 - Article
C2 - 25996426
AN - SCOPUS:84942433500
SN - 0275-004X
VL - 35
SP - 1964
EP - 1968
JO - Retina
JF - Retina
IS - 10
ER -